Navigation Links
Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
Date:3/13/2013

NDA resubmission filing, would be supplied to the FDA during the review within 60 days of the NDA resubmission.

In February, Orexigen initiated enrollment and randomized 242 patients into the Ignite Study. The Ignite Study is an open-label clinical trial designed to provide additional information regarding the real world weight loss potential of Contrave in combination with a commercially available comprehensive lifestyle intervention program, compared to patients who receive usual care of diet and exercise advice from the study site staff but who do not receive Contrave. The primary endpoint for this trial is change in body weight after 26 weeks. Orexigen anticipates receiving results from the Ignite Study by year-end 2013.

  • Empatic™, a fixed dose combination of bupropion SR and zonisamide SR, for the treatment of obesity: In a series of discussions with the FDA on the continued development of Empatic, the FDA stated that Phase 3 data for Empatic may be sufficient to support submission of an NDA without data from a cardiovascular outcomes trial. The FDA indicated that as long as the placebo-subtracted changes in body weight, blood pressure and heart rate for Empatic are similar to or more favorable than the placebo-subtracted changes observed with Contrave, and there are no signals of cardiovascular concern in the Empatic development program, reassuring results of a cardiovascular outcomes trial with Contrave will be sufficient.  In addition, while the FDA reiterated the belief that the teratogenicity potential for zonisamide is very concerning, the FDA will allow Phase 3 studies of Empatic to include women of childbearing potential who have a Body Mass Index that meets the FDA definition of overweight (>27kg/m2) in the presence of at least one weight-related comorbidity. Orexigen owns worldwide rights to Empatic. Prior to initiating Phase 3 studies of Empatic, the Company plans to seek
    '/>"/>

  • SOURCE Orexigen Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
    2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
    3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
    4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
    5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
    6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
    7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
    8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
    9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
    10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
    11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com ... available in its catalogue: The Market ... http://www.reportlinker.com/p02051938/The-Market-for-Medical-Devices-in-EMEA .html The European, Middle Eastern and ... medical devices. As part of its coverage, this ... concentrates on the EMEA medical device markets and ...
    (Date:8/20/2014)... Aug. 20, 2014  Quantum Materials Corporation (OTCQB:QTMM) ... of patent families from Bayer Technology Services GmbH, the ... Bayer AG of Leverkusen, Germany ... broad intellectual property protection for advances Quantum ... dot (QD) manufacturing. In addition, the Bayer patents ...
    (Date:8/19/2014)... , Aug. 19, 2014 Talyst, a market ... exhibiting at the 2014 NPPA Summer Conference in ... be showcasing its 340B software products and services.   ... splitting solutions, supplying over 400 customers with a variety ... 340B solutions including its latest solution, AutoSplit® Contract Pharmacy ...
    Breaking Medicine Technology:The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4Talyst Exhibits at the NPPA Summer Conference 2
    ... at American Society of Clinical Oncology 2009 Annual Meeting ... , , SAN FRANCISCO, June 2 Medivation, ... presentation of new clinical results from a Phase 1-2 ... castration-resistant prostate cancer (CRPC) patients. The new findings, ...
    ... , Panel Discussant Focuses on Longer Duration of Remission ... Complete Remissions Achieved with Standard Chemotherapy , , ... MTA: CTIC) announced today that at the poster and ... Section at the 2009 American Society of Clinical Oncology ...
    Cached Medicine Technology:Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 2Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 3Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 4Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 5Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 2Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 3Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 4Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 5Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 6
    (Date:8/20/2014)... News) -- Pigs, hearts transplanted into baboons survived for ... as previously achieved, researchers report. The work is ... organs to shorten transplant waiting lists. In this ... baboons, abdomens. The genetic engineering and new methods of ... the hearts to survive for more than a year. ...
    (Date:8/20/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... cancer cells grow may help doctors diagnose and treat the ... investigators have found that the deadliest skin cancers occur most ... a long history of sun exposure. These lesions also ... Rapid cell growth -- called "high mitotic rate" -- ...
    (Date:8/20/2014)... persistent and deadliest infectious diseases in the world, killing ... who study tuberculosis have long debated its origins. New ... Africa to seals and sea lions that brought the ... people there before Europeans landed on the continent. , ... Source of New World Human Tuberculosis," was published in ...
    (Date:8/20/2014)... New York, New York (PRWEB) August 20, 2014 ... associated with the use of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ... Liebhard LLP notes that two U.S. Senators from New ... (FDA) to seek a recall of the devices. In ... Charles Schumer, both Democrats, also implored the agency to ...
    (Date:8/20/2014)... contrast to evidence that the amygdala stimulates stress ... Research Center, Emory University have found that the ... during the early development of nonhuman primates. , ... Journal of Neuroscience . , The amygdala is ... important for responses to threatening situations and learning ...
    Breaking Medicine News(10 mins):Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Maturing brain flips function of amygdala in regulating stress hormones 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 3
    ... Red Compounds Financial Problems, According ... July 14 HealthLeaders-InterStudy, a,leading provider of healthcare ... the hospitals in the Los Angeles market are ... doing relatively well financially,and those that are barely ...
    ... and Blue Shield companies to,promote workplace wellness programs ... Recognizing that chronic,illness accounts for 75 percent ... on" approach to improving employee health and wellness ... prevention,and management. At a press briefing this morning ...
    ... of Health,and Hospitals announced its intent to award HMS ... and cost avoidance services,to the state,s Medicaid program. This ... the highest score in a competitive procurement process,for the ... the state, HMS recovered more than,$36 million for the ...
    ... Zimmer Holdings, Inc.,(NYSE: ZMH ; SWX: ZMH) statement:, ... that Zimmer,s,NexGen(R) knee implant had been recalled. In fact, ... used for minimally invasive,surgeries (MIS) and not the implant ... to a single surgical instrument and that additional,instrumentation options ...
    ... Bring Better Quality of Care and Improved Business Performance ... ... PITTSBURGH, July 14 Vocollect Healthcare Systems, Inc.,and SouthMed, Inc., ... healthcare market, announce a,strategic partnership, whereby SouthMed will resell AccuNurse,voice-assisted care ...
    ... Optimism is good for heart health, at least among ... Medical Center researcher Robert Gramling, M.D., D.Sc., found that ... cardiovascular disease actually experienced a three times lower incidence ... data did not support the same conclusion among women. ...
    Cached Medicine News:Health News:Fragmented Los Angeles Hospital Market Provides Health Systems with Little Leverage to Negotiate Higher Reimbursement 2Health News:Employers Take Active Role in Promoting Workplace Wellness 2Health News:Employers Take Active Role in Promoting Workplace Wellness 3Health News:Louisiana Department of Health and Hospitals Announces Intent to Award Cost Containment Services Contract to HMS 2Health News:Zimmer Holdings Issues Clarification Regarding NexGen Knee System 2Health News:Zimmer Holdings Issues Clarification Regarding NexGen Knee System 3Health News:SouthMed, Inc. and Vocollect Healthcare Systems Announce Reseller Agreement 2Health News:Positive thinking is prescription for the heart 2
    An enzyme-linked immuno-sorbent assay for the detectionand quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
    Jerome Halo Traction Units provide optimum immobilization for unstable injuries of the spine. The Generation 80 superstructure is available with either 2-point (serrated disk), or 3-point (flexion/ex...
    ... Boston Scoliosis Brace™ for neuromuscular ... a lightweight, soft, and easy ... maximum comfort. The Soft ... of non-cracking orthopedic grade copolymer ...
    An indirect immunofluorescence antibody test for the qualitative and semi-quantitative detection of endomysial antibodies (EMA) in human serum as an aid in the diagnosis of celiac disease and dermati...
    Medicine Products: